“Ronapreve is the first dedicated medicine developed for COVID-19 to receive marketing authorisation from the MHRA (Medicines and Healthcare products Regulatory Agency), representing a significant milestone in how the NHS is able to fight this disease,” said Paul McManus, COVID-19 Lead at Roche Products Ltd.
“Together with Regeneron, we’re grateful for the collaboration of the vaccine taskforce and NHS England in helping to bring this important antibody cocktail to treat and prevent acute COVID-19 across the UK,” he said.